These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

215 related articles for article (PubMed ID: 25240753)

  • 1. Characterization of the key antigenic components of pertussis vaccine based on outer membrane vesicles.
    Ormazábal M; Bartel E; Gaillard ME; Bottero D; Errea A; Zurita ME; Moreno G; Rumbo M; Castuma C; Flores D; Martín MJ; Hozbor D
    Vaccine; 2014 Oct; 32(46):6084-90. PubMed ID: 25240753
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Acellular pertussis vaccine based on outer membrane vesicles capable of conferring both long-lasting immunity and protection against different strain genotypes.
    Gaillard ME; Bottero D; Errea A; Ormazábal M; Zurita ME; Moreno G; Rumbo M; Castuma C; Bartel E; Flores D; van der Ley P; van der Ark A; F Hozbor D
    Vaccine; 2014 Feb; 32(8):931-7. PubMed ID: 24397896
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A Pertussis Outer Membrane Vesicle-Based Vaccine Induces Lung-Resident Memory CD4 T Cells and Protection Against
    Zurita ME; Wilk MM; Carriquiriborde F; Bartel E; Moreno G; Misiak A; Mills KHG; Hozbor D
    Front Cell Infect Microbiol; 2019; 9():125. PubMed ID: 31106160
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Rapid increase in pertactin-deficient Bordetella pertussis isolates, Australia.
    Lam C; Octavia S; Ricafort L; Sintchenko V; Gilbert GL; Wood N; McIntyre P; Marshall H; Guiso N; Keil AD; Lawrence A; Robson J; Hogg G; Lan R
    Emerg Infect Dis; 2014 Apr; 20(4):626-33. PubMed ID: 24655754
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Outer membrane vesicles obtained from Bordetella pertussis Tohama expressing the lipid A deacylase PagL as a novel acellular vaccine candidate.
    Asensio CJ; Gaillard ME; Moreno G; Bottero D; Zurita E; Rumbo M; van der Ley P; van der Ark A; Hozbor D
    Vaccine; 2011 Feb; 29(8):1649-56. PubMed ID: 21211579
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pertactin negative Bordetella pertussis demonstrates higher fitness under vaccine selection pressure in a mixed infection model.
    Safarchi A; Octavia S; Luu LD; Tay CY; Sintchenko V; Wood N; Marshall H; McIntyre P; Lan R
    Vaccine; 2015 Nov; 33(46):6277-81. PubMed ID: 26432908
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Assessment of safety and efficacy against Bordetella pertussis of a new tetanus-reduced dose diphtheria-acellular pertussis vaccine in a murine model.
    Kwon HJ; Han SB; Kim BR; Kang KR; Huh DH; Choi GS; Ahn DH; Kang JH
    BMC Infect Dis; 2017 Apr; 17(1):247. PubMed ID: 28376777
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Characterization of the immune response induced by pertussis OMVs-based vaccine.
    Bottero D; Gaillard ME; Zurita E; Moreno G; Martinez DS; Bartel E; Bravo S; Carriquiriborde F; Errea A; Castuma C; Rumbo M; Hozbor D
    Vaccine; 2016 Jun; 34(28):3303-9. PubMed ID: 27151884
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Outer membrane vesicles derived from Bordetella parapertussis as an acellular vaccine against Bordetella parapertussis and Bordetella pertussis infection.
    Bottero D; Gaillard ME; Errea A; Moreno G; Zurita E; Pianciola L; Rumbo M; Hozbor D
    Vaccine; 2013 Oct; 31(45):5262-8. PubMed ID: 24012570
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Synergic effect of genotype changes in pertussis toxin and pertactin on adaptation to an acellular pertussis vaccine in the murine intranasal challenge model.
    Komatsu E; Yamaguchi F; Abe A; Weiss AA; Watanabe M
    Clin Vaccine Immunol; 2010 May; 17(5):807-12. PubMed ID: 20357056
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pertussis Vaccine Candidate Based on Outer Membrane Vesicles Derived From Biofilm Culture.
    Carriquiriborde F; Martin Aispuro P; Ambrosis N; Zurita E; Bottero D; Gaillard ME; Castuma C; Rudi E; Lodeiro A; Hozbor DF
    Front Immunol; 2021; 12():730434. PubMed ID: 34603306
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of Outer Membrane Vesicles Obtained from Predominant Local Isolate of Boredetella pertussis as a Vaccine Candidate.
    Soltani MS; Noofeli M; Banihashemi SR; Shahcheraghi F; Eftekhar F
    Iran Biomed J; 2021 Nov; 25(6):399-407. PubMed ID: 34719226
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bordetella pertussis pertactin knock-out strains reveal immunomodulatory properties of this virulence factor.
    Hovingh ES; Mariman R; Solans L; Hijdra D; Hamstra HJ; Jongerius I; van Gent M; Mooi F; Locht C; Pinelli E
    Emerg Microbes Infect; 2018 Mar; 7(1):39. PubMed ID: 29559630
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bordetella pertussis Strain Lacking Pertactin and Pertussis Toxin.
    Williams MM; Sen K; Weigand MR; Skoff TH; Cunningham VA; Halse TA; Tondella ML;
    Emerg Infect Dis; 2016 Feb; 22(2):319-322. PubMed ID: 26812174
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pulsed-field gel electrophoresis, pertactin, pertussis toxin S1 subunit polymorphisms, and surfaceome analysis of vaccine and clinical Bordetella pertussis strains.
    Bottero D; Gaillard ME; Fingermann M; Weltman G; Fernández J; Sisti F; Graieb A; Roberts R; Rico O; Ríos G; Regueira M; Binsztein N; Hozbor D
    Clin Vaccine Immunol; 2007 Nov; 14(11):1490-8. PubMed ID: 17699837
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pertactin-deficient
    Barkoff AM; Mertsola J; Pierard D; Dalby T; Hoegh SV; Guillot S; Stefanelli P; van Gent M; Berbers G; Vestrheim D; Greve-Isdahl M; Wehlin L; Ljungman M; Fry NK; Markey K; He Q
    Euro Surveill; 2019 Feb; 24(7):. PubMed ID: 30782265
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The role of peptide loops of the Bordetella pertussis protein P.69 pertactin in antibody recognition.
    Hijnen M; de Voer R; Mooi FR; Schepp R; Moret EE; van Gageldonk P; Smits G; Berbers GA
    Vaccine; 2007 Aug; 25(31):5902-14. PubMed ID: 17597264
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Membrane Vesicles Derived from Bordetella bronchiseptica: Active Constituent of a New Vaccine against Infections Caused by This Pathogen.
    Bottero D; Zurita ME; Gaillard ME; Bartel E; Vercellini C; Hozbor D
    Appl Environ Microbiol; 2018 Feb; 84(4):. PubMed ID: 29180369
    [No Abstract]   [Full Text] [Related]  

  • 19. Increasing FIM2/3 antigen-content improves efficacy of Bordetella pertussis vaccines in mice in vivo without altering vaccine-induced human reactogenicity biomarkers in vitro.
    Queenan AM; Dowling DJ; Cheng WK; Faé K; Fernandez J; Flynn PJ; Joshi S; Brightman SE; Ramirez J; Serroyen J; Wiertsema S; Fortanier A; van den Dobbelsteen G; Levy O; Poolman J
    Vaccine; 2019 Jan; 37(1):80-89. PubMed ID: 30478007
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bordetella pertussis and pertactin-deficient clinical isolates: lessons for pertussis vaccines.
    Hegerle N; Guiso N
    Expert Rev Vaccines; 2014 Sep; 13(9):1135-46. PubMed ID: 24953157
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.